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Abstract
The humoral immune response to SARS-CoV-2 results in antibodies
against spike (S) and nucleoprotein (N). However, whilst there are
widely available neutralization assays for S antibodies, there is no
assay for N-antibody activity. Here, we present a simple in vitro
method called EDNA (electroporated-antibody-dependent neutral-
ization assay) that provides a quantitative measure of N-antibody
activity in unpurified serum from SARS-CoV-2 convalescents. We
show that N antibodies neutralize SARS-CoV-2 intracellularly and
cell-autonomously but require the cytosolic Fc receptor TRIM21.
Using EDNA, we show that low N-antibody titres can be neutraliz-
ing, whilst some convalescents possess serum with high titres but
weak activity. N-antibody and N-specific T-cell activity correlates
within individuals, suggesting N antibodies may protect against
SARS-CoV-2 by promoting antigen presentation. This work high-
lights the potential benefits of N-based vaccines and provides an
in vitro assay to allow the antibodies they induce to be tested.
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Introduction
The immune response to SARS-CoV-2 results in a strong antibody
response to both spike (S) and nucleoprotein (N) (Li et al, 2020).
Antibodies against these two antigens have been widely used as
diagnostics of past or present SARS-CoV-2 infection. Anti-S antibod-
ies (or S antibodies) have been shown to neutralize SARS-CoV-2
and inhibit its replication, leading to their use as a rapid and effec-
tive antiviral treatment. Research into S antibodies has also played a
vital role in the development of S-based vaccines, both by demon-
strating that raising S antibodies is a worthwhile objective and by
providing neutralization assays that allow correlates of protection to
be established, a vital measure of vaccine efficacy. In contrast,
despite the fact that anti-N antibodies (or N antibodies) are found in
SARS-CoV-2 convalescents at levels that equal or exceed those of S
antibodies (Rydyznski Moderbacher et al, 2020), there has been
comparatively less investigation into their relevance beyond diag-
nostics. This is largely because unlike with anti-S antibodies, there
is no assay that can measure if N antibodies block SARS-CoV-2
infection. However, it seems unlikely that a robust anti-N response
plays no role in immunity to SARS-CoV-2. Studies in mice using
murine hepatitis virus (MHV; a murine b-coronavirus with brain
and liver tropism) have shown that passively transferred N antibod-
ies are protective (Nakanaga et al, 1986; Lecomte et al, 1987).
Indeed antibodies to internal antigens like N have been shown to
prevent infection by arenaviruses (Richter & Oxenius, 2013; Straub
et al, 2013), ebolavirus (Wilson et al, 2000), human cytomegalo-
virus (HCMV; Bootz et al, 2017), human immunodeficiency virus
(HIV; Excler et al, 2014; Mayr et al, 2017), influenza viruses (Samb-
hara et al, 2001; Carragher et al, 2008; LaMere et al, 2011) and
vaccinia virus (Moss, 2011). Crucially however, because internal
antigens are usually hidden inside the virion, antibodies against
them do not bind infectious viral particles. Consequently, N anti-
bodies and similar typically do not block infectious entry of viruses
into cells in standard in vitro assays and are described as “non-
neutralizing”. The mechanisms behind the immune protection
provided by non-neutralizing antibodies like N antibodies remain
largely unknown.
Importantly, without functional data on SARS-CoV-2 N antibod-
ies or an available assay to measure protective activity, there is less
incentive to invest significant global effort into developing N-based
vaccines. Meanwhile, although S-based vaccines are proving highly
effective against SARS-CoV-2 transmission, there is growing
evidence that emerging spike variants of SARS-CoV-2 are less
susceptible to the immunity they induce (preprint: Garcia-Beltran
et al, 2021; preprint: McCallum et al, 2021). The emergence of spike
variants has also been seen in patients treated with convalescent
plasma/monoclonals (Avanzato et al, 2020). The observed rapid
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mutation of SARS-CoV-2 spike underlies the widely held view that
new vaccines may be required seasonally, unless the virus can be
globally eradicated. One solution is to keep making new variant S-
vaccines, but another is to use a combined approach immunizing
with a vaccine that contains both S and N, making it much less
likely for a resistant virus to emerge. All 10 currently authorized
and approved SARS-CoV-2 vaccines are S-based. We therefore set
out to develop an assay for N-antibody activity, both to provide
evidence for the inclusion of N as a candidate vaccine antigen and
to allow N-based vaccines to be efficiently tested. The assay we
developed, named EDNA (for electroporated-antibody-dependent
neutralization assay), provides the only in vitro method that allows
the antiviral activity of N antibodies in SARS-CoV-2 convalescent
serum to be rapidly and quantitatively tested.
Results
Antibodies mediate intracellular neutralization of MHV
As MHV is a class 1 biosafety pathogen, and N antibodies are
known to play a role in immunity to MHV in vivo (Nakanaga et al,
1986; Lecomte et al, 1987), we decided to use this as a model
system to develop an assay that could be used to measure N-
antibody activity. First, we established a system to quantify MHV
replication based on syncytia formation and cytopathic effect (CPE).
Live phase-contrast microscopy revealed cell–cell fusion occurs 8–
10 h after MHV-A59 infection and peaks at 30 h, followed by lysis
and cell death (Movie EV1, Appendix Fig S1A). Plotting either cell
area quantified from live imaging or cell viability determined by
total ATP levels at 48 h post-infection against virus dilution gave
almost identical dose–response curves and TCID50 values
(Appendix Fig S1B–D). Thus, live-cell imaging can be used to follow
cytopathic MHV infection over time and accurately quantify virus
titre. Using this approach, we tested the neutralization capacity of a
polyclonal antiserum raised against disintegrated, purified MHV-
A59 virions (Rottier et al, 1981) that includes antibodies against
both MHV-A59 S and N (Appendix Fig S1E). Antiserum was added
to the cell media, or delivered directly into the cytosol by adapting
our previously described Trim-Away technology (Clift et al, 2017).
In Trim-Away, antibodies are electroporated into cells and form a
complex with their protein target. This complex is recognized by the
cytosolic Fc receptor and E3 ubiquitin ligase TRIM21 (James et al,
2007), which uses ubiquitination to recruit the proteasome and
mediate complex degradation (Mallery et al, 2010; Kiss et al, 2021).
Remarkably, the antiserum reduced MHV-A59 replication 10-fold
more potently when delivered intracellularly than added extracellu-
larly (Fig 1A–C). This suggests that there are antibodies present in
the antiserum that can bind to viral proteins post-fusion in the
cytosol and neutralize replication.
To test if anti-N antibodies are responsible for the block to
replication, we electroporated L929 cells with serial dilutions of an
anti-N monoclonal antibody (Leibowitz et al, 1987) or a control
anti-GFP antibody and infected with MHV-A59. Strikingly, electro-
poration of the anti-N monoclonal antibody completely neutralized
MHV-A59, whereas the control anti-GFP antibody had no effect
(Fig 1D–F). Previously, we have shown that intracellular antibody-
dependent neutralization (ADIN), in which non-enveloped viruses
pre-bound by antibody are neutralized after entry into the cytosol, is
dependent on TRIM21 (Mallery et al, 2010). Upon binding to
antibody-coated viruses, TRIM21 mediates rapid proteasomal- and
VCP-dependent viral degradation (Hauler et al, 2012) and thereby
blocks replication. To test whether this is also the case for electropo-
rated anti-N antibodies and MHV-A59, we generated CRISPR
TRIM21 knockout L929 cells (Appendix Fig S1F). TRIM21 knockout
did not affect cell proliferation or cytopathic MHV-A59 infection in
the absence of serum or antibody (Appendix Fig S1G). However,
TRIM21 knockout cells could no longer neutralize MHV-A59 when
electroporated with MHV antiserum or anti-N monoclonal antibody,
suggesting that intracellular neutralization is completely TRIM21-
dependent (Fig 1G and H). To further confirm the role of TRIM21 in
intracellular neutralization, we co-electroporated anti-N antibody
with excess recombinant protein A/G, which competes with TRIM21
for binding to IgG Fc (Keeble et al, 2008). The presence of protein
A/G did not impact antibody electroporation efficiency or localiza-
tion in the cytosol (Appendix Fig S1H and I). However, co-
electroporation of protein A/G with anti-N antibody completely
abolished intracellular neutralization of MHV-A59 in otherwise
wildtype cells (Fig 1H). These data suggest that anti-N antibodies
neutralize MHV-A59 intracellularly by recruiting the cytosolic Fc
receptor TRIM21. In both ADIN and Trim-Away, TRIM21 exerts its
effects by targeting protein:antibody complexes for degradation. We
therefore tested whether electroporated anti-N antibodies are caus-
ing degradation of MHV-A59 N protein. To do this, we allowed N-
protein expression for 4 h post-infection, blocked further N-protein
expression by addition of cycloheximide (CHX) and then electropo-
rated anti-N or anti-GFP antibodies or a no antibody control. Elec-
troporation in the absence of antibody did not change N-protein
levels (Appendix Fig S1J). Electroporation of anti-N but not anti-
GFP antibody led to a reduction in N-protein levels (Fig 1I). This is
consistent with the block to MHV replication being caused by N-
protein degradation. Taken together, the data show that our
electroporation-based method can be used to measure the activity of
N antibodies in vitro. To distinguish this from the natural process of
antibody-dependent intracellular neutralization (ADIN), we desig-
nated the approach “electroporated-antibody-dependent neutraliza-
tion assay” (EDNA).
EDNA can be used to measure intracellular antibody
neutralization of SARS-CoV-2
Next, we investigated whether EDNA could be used to investigate
the N-antibody response to SARS-CoV2. To do this, we used a clini-
cal isolate of SARS-CoV-2/human/Liverpool/REMRQ0001/2020 and
Vero cells modified to stably express SARS-CoV-2 entry factors
ACE2 and TMPRSS2 (Papa et al, 2021). We added polyclonal rabbit
anti-N antibodies or control rabbit IgG to Vero ACE2/TMPRSS2 with
or without electroporation and after 24 h infected them with SARS-
CoV-2. To assess virus replication, we lysed the cells 24 h after
infection and checked levels of genomic viral RNA by RT–qPCR.
Electroporation of N antibodies reduced viral RNA by 3-logs
(Fig 2A). Importantly, the same sera in the absence of electropora-
tion had no impact on replication, indicating that N antibodies must
be inside the cell to mediate neutralization. To confirm these results,
we measured the effect of anti-N sera on the production of infectious
particles after 24 h by plaque assay. In agreement with RT–qPCR,
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Figure 1. Electroporated-antibody-dependent neutralization assay (EDNA) for coronavirus.
A A titration of anti-MHV polyclonal serum was added either directly to media (extracellular) or electroporated into L929 cells (intracellular), and then, cells were
infected with MHV-A59. The kinetics of cell growth was monitored by measuring total cell area.
B Phase-contrast images of cells at 48 h post-infection. Scale bar = 200 µm.
C At 48 h post-infection, the viability of cells infected with MHV-A59 in the presence of intracellular or extracellular antiserum was determined by ATP luminescence
assay. Increasing doses of antiserum results in increased cell survival.
D Kinetics of cell growth following MHV-A59 infection in the presence of a titration of electroporated anti-N antibody.
E Phase-contrast images of cells at 48 h post-infection. Scale bar = 200 µm.
F Quantification of cell viability by ATP luminescence assay at 48 h post-infection in the presence of electroporated anti-N or anti-GFP antibodies.
G, H WT or TRIM21 KO L929 cells were infected with MHV-A59 in the presence of electroporated polyclonal antiserum (G) or anti-N antibody (H) and quantified by cell
area 48 h later. Co-electroporation of protein A/G with anti-N antibody into WT cells mimics the TRIM21 KO phenotype.
I L929 cells were infected with MHV-A59 for 4 h, and then, cyclohexamide (CHX) was added to block further viral protein synthesis. After 5 h, cells were
electroporated with anti-N or anti-GFP antibodies and left for a further 3 h before being western blotted for cellular N protein levels (* denotes a non-specific
band).
Data information: Data were analysed using a Student’s t-test. Error bars depict the mean +/- SEM. All data represent at least two independent replicates.
Source data are available online for this figure.
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we observed a significant reduction in production of new infectious
particles in the presence of electroporated N antibodies (Fig 2B).
Intracellular neutralization was antibody dose-dependent, consistent
with the MHV data and previous ADIN experiments (McEwan et al,
2012) (Fig 2C and D). We next investigated whether intracellular
neutralization of SARS-CoV-2 is TRIM21-dependent. We transduced
a previously characterized TRIM21 knockout HEK293T clone with
ACE2, to make it sensitive to SARS-CoV-2 entry, and then reconsti-
tuted TRIM21 expression with lentivirus encoding TRIM21 under its
endogenous promoter or transduced with an empty vector control
(Fig 2E; Zeng et al, 2019). Electroporation/infection experiments
were then carried out as before in both cell lines. Neutralization of
SARS-CoV-2 by N-antibody electroporation was observed by both
RT–qPCR (Fig 2F) and plaque assay (Fig 2G) but only in cells recon-
stituted with TRIM21. These results confirm that N-specific antibod-
ies mediate TRIM21-dependent neutralization of SARS-CoV-2 and
that EDNA can be used to quantify this activity.
EDNA provides a functional assay for N antibodies in SARS-CoV-2
convalescent sera
Anti-N antibodies reach high titres in many seroconverted individu-
als (preprint: Hachim et al, 2020) and are widely used as a diagnos-
tic for previous infection with SARS-CoV-2 (Krammer & Simon,
2020). However, there is no equivalent to an S-antibody neutraliza-












































































































































































Figure 2. N antibodies inhibit SARS-CoV-2 replication intracellularly.
A, B Vero cells OE ACE2 and TMPRSS2 were infected with SARS-CoV-2 in the presence of IgG or anti-N antibodies added directly into media or electroporated into cells.
Viral replication was then determined by RT–qPCR (A) or plaque assay (B). Electroporation of anti-N antibodies significantly inhibits SARS-CoV-2 replication
(***P < 0.0002).
C, D As with A&B, except with a titration of electroporated anti-N antibodies.
E Western blot of 293T cells and 293T ACE2 OE/TRIM21 KOs alone or reconstituted with empty vector (EV) or an endogenous promoter-driven TRIM21 vector (T21)
(Zeng et al, 2019).
F, G 293T ACE2 OE/TRIM21 KO cells reconstituted with EV or TRIM21, electroporated with IgG or anti-N antibodies, and infected with SARS-CoV-2. Viral replication was
then determined by RT–qPCR (F) or plaque assay (G). Electroporation of anti-N antibodies significantly inhibits SARS-CoV-2 replication only in TRIM21-
reconstituted cells (*P < 0.05).
Data information: All data represent at least three independent replicates. Error bars depict the mean  SEM. Statistical comparisons were performed using a one-way
(A, B) or two-way (F, G) ANOVA.
Source data are available online for this figure.
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provide such an assay. We tested a small cohort of four SARS-CoV-2
convalescents (SARS-CoV-2 seropositivity confirmed by luminex
testing) and two sero-negatives for their antibody responses using a
capillary-based protein detection system (Jess, ProteinSimple). Jess
measures native antibody–antigen binding, meaning that quan-
tification of the chemiluminescent signal provides a measure analo-
gous to the antibody titre obtained by ELISA (i.e. it is a combination
of specific antibody concentration and affinity). We observed a
range of responses; some sera displayed only limited reactivity to
any SARS-CoV-2 antigen, others reacted robustly against N but
weakly against S, and some had both strong anti-N/strong anti-S
profiles (Fig 3A and B). The data show that a good dynamic range
in antigen reactivity is capable of being measured but a larger
cohort would be required to draw any conclusions about antibody
portfolios. Next, we electroporated the sera into 293T ACE2 cells
and infected them 24 h later with SARS-CoV-2. Infection levels were
assessed after a further 24 h by plaque assay. Infection was
decreased > 10-fold in cells electroporated with sera that had a
strong anti-N response (Fig 3C). In contrast, sera with essentially no
anti-N antibodies were unable to neutralize infection. To establish
whether activity in the polyclonal sera is dependent upon TRIM21,
we compared infection in 293T TRIM21 KO ACE2 cells reconstituted
with either empty vector or TRIM21. Only in TRIM21-reconstituted




Figure 3. EDNA detects intracellular neutralization activity in SARS-CoV-2 convalescent sera.
A Capillary-based protein detection (Jess) of antibodies against SARS-CoV-2 antigens in convalescent sera.
B Quantification of antigen-specific antibodies in convalescent sera.
C 293T cells OE ACE2 infected with SARS-CoV-2 in the presence of electroporated convalescent sera. There are statistically significant differences in the ability of serum
from different individuals to inhibit viral replication intracellularly (**P < 0.005, *P < 0.05).
D 293T ACE2 OE/TRIM21 KOs reconstituted with either empty vector (EV) or TRIM21-expressing vector (TRIM21) infected with SARS-CoV-2 in the presence of
electroporated convalescent sera. Intracellular neutralization of viral replication is only observed in cells reconstituted with TRIM21 (**P < 0.005).
Data information: All data represent at least three independent replicates. Error bars depict the mean  SEM. Statistical comparisons were performed using a one-way
(C) or two-way (D) ANOVA.
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SARS-CoV-2 convalescents make potently neutralizing anti-N
antibodies and this correlates with increased levels of
N-specific T cells
Having validated that EDNA could be used to assess convalescent
serum samples, we collected a larger panel of sera from serocon-
verted staff at Royal Papworth Hospital NHS Foundation Trust
(RPH), Cambridge University Hospitals NHS Foundation Trust
(CUH) in Cambridge and The Queen Elizabeth Hospital NHS Foun-
dation Trust (QEH) in Kings Lynn, UK. As before, we used Jess to
quantify the antibody responses to N, S, S1, S2 and RBD (Fig 4A
and Appendix Fig S2). There was a wide range in response strength,
with chemiluminescence varying over > 4-logs. Choosing two of the
strongest responders to N protein, we performed a titration to estab-
lish the linear range of the binding assay (Appendix Fig S3). Sera
containing particularly strong responses were diluted and re-
measured to be within the linear range. The titration also confirmed
that measured weak responders are still well above the threshold
for detection. Performing a comparison between the antigens, we
observed a weak correlation between anti-N and anti-S, S1, S2 or
RBD responses (R2 between 0.17–0.32) (Appendix Fig S4A–D).
Nevertheless, there was considerable variation with substantial
numbers of individuals possessing monodominant responses (strong
N or S but not both).
Next, we electroporated a single dilution of each serum into Vero
ACE2/TMPRSS2 cells, challenged them with SARS-CoV-2 and quan-
tified infection by RT–qPCR (Fig 4B). Comparing intracellular
neutralization activity with antibody titres to each antigen in turn
showed a trend between neutralization potency and strength of
response to N but not to other antigens (Fig 4C and Appendix Fig
S2F–I). This is consistent with the expected antigen topology upon
viral entry, in which S antigen will remain at the plasma membrane
following membrane fusion whilst N is delivered into the cytosol
with the viral genome. To further confirm that it is anti-N and not
anti-S antibodies that are responsible for the observed intracellular
neutralization, we tested serum possessing a strong S/weak N anti-
body response (Appendix Fig S2A, Fig 4A) and confirmed that
whilst it is unable to neutralize intracellularly, it potently neutralizes
extracellularly (Appendix Fig S4E vs. Fig 4B). Whilst sera with the
highest titre anti-N responses was usually the most strongly neutral-
izing, there were exceptions to this trend. Four serum samples
possessed neutralization activity that was unexpectedly high given
their modest anti-N titres, whilst one sample had a high anti-N titre
but gave modest neutralization (Fig 4A–C; green and red bars,
respectively). This may be because antibodies with unusually high
affinity but present at low levels can exert a protective effect whilst
conversely, specific antibodies present at high concentrations but
with weak affinities may not. Comparison of the Jess and neutraliza-
tion data also suggests that there is a threshold effect, in that neutral-
ization is only observed in sera with a chemiluminescent signal
> 106 (Fig 4C). To determine whether this is due to the nature of the
antibodies in these samples or whether there is a functional thresh-
old for intracellular neutralization of SARS-CoV-2, we electroporated
a titration of two potently neutralizing serum samples. We observed
similar neutralization curves for both, indicating that once diluted to
a chemiluminescent signal < 106, neutralization activity is largely
lost (Fig 4D and Appendix Fig S3). This suggests that there is indeed
a functional threshold for intracellular neutralization of SARS-CoV-2.
Antibodies against internal antigens like nucleoprotein are gener-
ated during the immune response to most enveloped viruses (Sch-
maljohn, 2013). Importantly, although anti-N antibodies do not
block infection when added directly to cultured cells in vitro, they
provide protective immunity in vivo. This is likely because the anti-
bodies are not efficiently taken up by cells in vitro, a step we bypass
in EDNA by using electroporation. How anti-N antibodies are
imported by cells in vivo and provide protection is not well under-
stood. Recently, we showed that anti-N antibodies help to clear
LCMV infection by promoting the induction of N-specific cytotoxic T
cells (Caddy et al, 2021). This is thought to occur as a result of
cross-presentation: nucleoprotein immune complexes (N:Ab) are
imported by antigen-presenting cells and detected by TRIM21, lead-
ing to proteasomal degradation and the generation of N peptides for
MHC class I presentation. Both B and T cells responses contribute to
SARS-CoV-2 immunity and almost all convalescents have both
(Sette & Crotty, 2021). We therefore considered that the same
immune mechanism of antibody:T cell synergy we observed during
LCMV infection may be operating during the response to SARS-CoV-2.
To test this hypothesis, we isolated fresh PBMCs from SARS-CoV-2
convalescents and used ELISpot to quantify their N-specific T cells.
Upon stimulation with an N peptide library, we observed a  100-fold
range in the number of specific (interferon expressing) cells between
individuals (Fig 4E). Comparing the number of N-specific T cells and
intracellular neutralizing activity within each individual revealed a
modest correlation, consistent with the hypothesis that N antibodies
may contribute to protection against SARS-CoV-2 by promoting T-cell
immunity (Fig 4F). Of note, a similar correlation performed using anti-
N binding titre failed to give a convincing correlation (Fig 4G). This
result highlights the importance of measuring the neutralization
activity of anti-N antibodies, not just their levels in serum, and the
utility of EDNA.
Discussion
Here, we have described an in vitro assay called EDNA that can
quantify the activity of N antibodies produced upon SARS-CoV-2
infection, in the same way that classical neutralization assays are
used to quantify S-antibody activity (for overview, see Summary
Figure). EDNA allows the measurement of N-antibody activity in
SARS-CoV-2 convalescent sera, can be used in conjunction with
standard readouts like RT–qPCR and plaque assay and has a large
dynamic range. EDNA uses electroporation to deliver antibodies
directly into the cytoplasm of cells, before exposing them to virus.
This allows antibodies that target antigens normally hidden inside
the viral envelope to be tested for their ability to disrupt infection.
Importantly, this means that antiviral activity can be detected in
antibody sera that on the basis of low anti-S titres would normally
be characterized as non-neutralizing (e.g. RPH38, CUH186,
CUH066; Fig 4A and B, Appendix Fig S2A–D). Neutralizing antibod-
ies typically work extracellularly by inhibiting receptor binding and/
or preventing fusion of the viral envelope with the cell membrane.
In EDNA experiments with both MHV and SARS-CoV-2, and with
both polyclonal sera and monoclonal anti-N antibodies, we show
that intracellular neutralization is dependent upon the cytosolic Fc
receptor and E3 ubiquitin ligase TRIM21. TRIM21 has previously
been shown to mediate antibody-dependent intracellular
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neutralization (ADIN). In ADIN, antibodies pre-bound to a non-
enveloped virus recruit TRIM21 to cause capsid degradation and we
hypothesize that a similar mechanism of degradation operating
against N protein blocks viral replication during EDNA. N protein
protects the coronavirus genome and stabilizes sub-genomic RNA





Figure 4. SARS-CoV-2 convalescents make potently neutralizing N antibodies whose activity correlates with the number of active N-specific T cells.
A Capillary-based protein detection (Jess) of N antibodies in convalescent sera, quantified by chemiluminescence.
B Quantification of SARS-CoV-2 intracellular neutralization by electroporated convalescent sera using EDNA and RT–qPCR (as % of PBS condition).
C Correlation between N-antibody titre, as calculated by Jess, and intracellular neutralization (fold decrease in SARS-CoV-2 replication), as measured by EDNA, in
convalescent sera from multiple individuals.
D Intracellular neutralization of SARS-CoV-2 by titrated serum from two strongly N antibody-positive individuals.
E ELISpot measuring IFNc production in T cells from SARS-CoV-2 convalescents upon stimulation with a peptide library covering N-protein.
F Correlation between N-specific T-cell activity and intracellular neutralization activity.
G Correlation between N-specific T-cell activity and N-antibody titre.
Data information: All data represent at least three independent replicates. Error bars depict the mean  SEM. Statistical analysis was performed using a semilog
non-linear fit (F, G).
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for viral replication. Consistent with this, we observe N protein
degradation during EDNA experiments with MHV, whilst in SARS-
CoV-2 experiments intracellular neutralization activity correlates
with N antibody but not S-antibody titre. N-antibody binding titres
are not always predictive of intracellular neutralizing capacity
however, as sera can differ in titre by > 10-fold but possess similar
neutralization activity (e.g. RPH308 vs. CUH186; Fig 4A and B).
Based on previous data, we predict that off-rates between antibody–
antigen (Bottermann et al, 2016) and antibody-TRIM21 (Foss et al,
2016) will be predictive of intracellular neutralization potency. In
contrast with extracellular entry-blocking neutralization, we expect
epitope specificity to be less important as long as the epitope is
present in the folded state and TRIM21 binding can take place.
Infection with most enveloped viruses results in high titre anti-
bodies against internal antigens and whilst these are typically non-
neutralizing in vitro (at least as characterized in standard assays)
they are often highly protective in vivo (Schmaljohn, 2013). Based
on our results here, and recently published (Caddy et al, 2021), we
propose that ADIN may provide one underlying mechanism by
which non-neutralizing antibodies mediate protection. However,
ADIN does not explain how and where non-neutralizing antibodies
like those against N protein meet their antigen. EDNA is an in vitro
assay in which antibodies are artificially delivered directly into the
cytosol. This is a limitation of the method and does not address the
issue of cellular uptake and cytosolic import during natural SARS-
CoV-2 infection in vivo. Whilst antibodies are readily taken up by
most tissues, they are normally recycled back out of the cell by the
neonatal Fc receptor FcRn. There is evidence that antibodies can be
imported into the cytosol, typically during disease, but the mecha-
nisms involved are unclear (Congdon et al, 2013). Indeed, it is the
absence of a well-understood mechanism to explain how antibodies
against internal viral antigens like the nucleoprotein meet their
target has discouraged study into their role in protective immunity.
The context in which cytosolic antibody import is best under-
stood is during antigen presentation, where both passive
mechanisms involving membrane disruption and leakage into the
cytosol (Reis e Sousa & Germain, 1995) and active mechanisms of
import requiring the channel forming protein Sec61 (Mukai et al,
2011) and the ATPase VCP (Ackerman et al, 2006) have been
proposed. Most recently, the receptor DNGR-1 has been shown to
promote phagosomal rupture by inducing NADPH oxidase activity
(Canton et al, 2021). Previous work on viruses such as influenza
has demonstrated a synergistic link between N-specific antibodies
and N-specific cytotoxic T lymphocytes (CTLs; LaMere et al, 2011;
Laidlaw et al, 2013). Moreover, we recently showed that TRIM21
uses anti-N antibodies to promote N-specific CTLs and thereby
protect against LCMV infection (Caddy et al, 2021). These data
suggested that TRIM21 can detect immune complexes upon their
import into antigen-presenting cells and cause their rapid proteaso-
mal degradation, leading to the efficient generation of peptides for
MHC class I presentation. We hypothesize that a similar process
may be operating during SARS-CoV-2 infection. Consistent with
this, we find a correlation between N-antibody neutralization as
measured by EDNA and N-specific T cells as measured by ELISpot.
Convalescents with potently neutralizing N antibodies possess
increased numbers of N-specific T cells. Moreover, we observed
individuals (e.g. RPH38; Fig 4A, B, E and Appendix Fig S2A) with
low S titres but both strong anti-N neutralization and high
numbers of N-specific T cells. There may be differences in the
immediate protection afforded by N- vs S-directed B- and T-cell
immunity. Perhaps more importantly, the longevity of responses
to each antigen may differ as could their ability to protect against
new viral variants. Notably, N-specific T-cell responses in SARS-
CoV convalescents could be detected 17 years after infection (Le
Bert et al, 2020) and were cross-reactive with N from SARS-CoV-2.
Whilst our findings require further validation in larger cohorts,
and in studies correlating responses with patient outcomes, they
provide evidence both of the utility of EDNA and the importance
of considering N-based vaccines as a viable alternative to S-only
approaches.
Materials and Methods
Reagents and Tools table
Reagent/Resource Reference or Source Identifier or catalog number
Experimental models
Vero CCL-81 ATCC CCL-81
HEK293T ATCC CRL-3216
L929 ATCC CCL-1
Vero ACE2/TMPRSS2 Papa et al (2021) Vero ACE2/TMPRSS2
HEK293T ACE2 Papa et al (2021) HEK293T ACE2
SARS-CoV-2/human/Liverpool/REMRQ0001/2020 Papa et al (2021) Kind gift from Lance Turtle (University of Liverpool)
and David Matthews and Andrew Davidson (University
of Bristol)
MHV-A59 Kind gift from Ian Goodfellow (Cambridge University)
Antibodies
MHV-A59 polyclonal antiserum raised against disintegrated,
purified MHV-A59 virions (Rottier et al, 1981)
Dr. Peter Rottier (Utrecht
University).
MHV-A59 polyclonal antiserum
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Reagents and Tools table (continued)
Reagent/Resource Reference or Source Identifier or catalog number
Monoclonal Anti-Murine Coronavirus Nucleocapsid (N) Protein,
Clone 1.16.1
BEI Resources, NIAID, NIH NR-45106
Mouse anti-GFP antibody Rockland 9F9.F9; 600-301-215
Rabbit anti-N antibodies Millipore ABIN129544
Rabbit normal IgG Millipore 12-370
Rabbit anti-TRIM21 Abcam ab207728
Mouse TRIM21 Santa Cruz sc-21367
Rabbit anti-Vinculin Abcam ab217171
Rabbit anti-COX IV LICOR 926-42214
HRP-coupled secondary anti-mouse light chain specific Millipore AP200P
Anti-rabbit light chain specific Millipore MAB201P
Anti-SARS-CoV-2 S Invitrogen PA1-41165
Anti-IFN-c antibody 1-D1K Mabtech cat#3420-3
Anti-biotin monoclonal antibody Vector Labs #SP-3020
IgG-A488 Molecular Probes A11055
Oligonucleotides and other sequence-based reagents
For long lists of oligos or other sequences please refer to the relevant Table(s) or EV Table(s)
CDC-N2 (IDT 2019-nCoV RUO kit) CDC 143503
SARS-CoV-2_N_Positive control RNA IDT 10006625
Chemicals, Enzymes and other reagents (e.g. drugs, peptides, recombinant proteins, dyes etc.)
Methylene blue Sigma M4159
Toluidine blue Sigma M4159
Formaldehyde Sigma T3260
ATPlite 1-step luminescence reagent Perkin Elmer 6016731
RIPA buffer Cell Signalling Technology CST-9806
NuPAGE LDS Sample Buffer Thermo Fisher NP0007
NuPAGE 4–12% Bis-Tris Gels Thermo Fisher NP0326BOX
Protease Inhibitor Cocktail Roche P8340
ECL Western Blotting Detection Reagent Amersham RPN2106
SARS-CoV-2 serology assay Bio-Techne SA-001
Separation module 12–240 kDa Bio-Techne SM-W004
RNAsecure Invitrogen AM7006
Luna® Universal Probe One-Step NEB E3006
PepTivator SARS-CoV-2 protein N peptide pool Miltenyi Biotec 130-126-698
Lymphoprep StemCell 07801
ELISpot MAIP plates Millipore MAIPS4510
8-well chambered coverslips Ibidi 41122111
Cas9 protein IDT #1081060




GraphPad Prism 9 GraphPad
Other
PMA-Lite LED Photolysis blue light device Generon E90002
Jess capillary protein detection system ProteinSimple
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Reagents and Tools table (continued)
Reagent/Resource Reference or Source Identifier or catalog number
Neon Transfection System Thermo Fisher MPK5000
IncuCyte S3 Sartorius IncuCyte S3
ABI StepOnePlus PCR System Life Technologies
ELISpot reader AID ispot, Autoimmun
Diagnostika
Eclipse EC800 flow cytometer Sony
Lumascope LS720 widefield microscope Etaluma
PHERAstar FS plate reader BMG
Methods and Protocols
MHV EDNA
1 Wash cells (e.g. Vero ACE2/TMPRSS2) in PBS and resuspend
in Buffer R (Thermo Fisher) at a concentration of between 0.1–
1 × 108 cells ml1 depending on experiment.
2 For each electroporation reaction, mix 0.1–1 × 106 cells
(10.5 µl) with 2 µl of the antibody/serum/protein to be delivered.
3 Take up electroporation mixture into a 10-µl Neon Pipette Tip
and electroporate using a Neon Electroporator using the
following settings: 1,400 V, 20 ms, 2 pulses. For non-
electroporated controls, skip this step.
4 Transfer electroporated cells to medium supplemented with
10% serum without antibiotics.
5 Plate 1 × 104 electroporated L929 cells in 96-well plates in trip-
licates. The next day, infect cells with MHV-A59 at MOI = 1.
6 Image using an IncuCyte system for 48 h within a 37°C, 5%
CO2 humidified incubator.
7 Quantify total cell area using IncuCyte software by detecting
the outline of cells. Mock-infected cells (no virus) will rapidly
proliferate to form a confluent monolayer over the course of
48 h (Appendix Fig S1A).
8 Check for a typical cell growth curve consisting of a short lag
phase followed by logarithmic growth and then a stationary
phase as the cells formed a confluent monolayer. In contrast,
cells infected with MHV-A59 should begin to fuse after 8–10 h,
and by 30 h post-infection large syncytia occupy the majority
of the monolayer. Between 30 and 48 h post-infection, the
syncytia should have lysed and detached from the dish and the
remaining cells exhibited a rounded morphology typical of
dead of dying cells. The cell growth curves should show an
incremental shift towards the no virus control with each serial
dilution of viral stock (Appendix Fig S1B, circles – black to
grey to white). Plotting the cell area values at 48 h post-
infection against virus dilution should give a typical dose–
response curve that can be fitted with a non-linear regression
curve to calculate a TCID50 value (in our case, 2.12 × 108
TCID50/ml; Appendix Fig S1C).
9 After imaging is completed, the same cells should be analysed
by ATP luminescence assay at 48 h post-infection to quantify
cell viability.
10 For ATP assay, cells in 100 µl media in dark 96-well plates
should be lysed with 100 µl/well of ATPlite 1-step lumines-
cence reagent according to manufacturer instructions.
11 Quantify luminescence using a luminometer (e.g. BMG PHER-
Astar FS plate reader). Plotting these values against virus dilu-
tion should give an almost identical dose–response curve and
TCID50 value (Appendix Fig S1D).
SARS-CoV-2 EDNA
1 Wash cells (e.g. Vero ACE2/TMPRSS2) in PBS and resuspend
in Buffer R (Thermo Fisher) at a concentration of between 0.1–
1 × 108 cells ml1 depending on experiment.
2 For each electroporation reaction, mix 0.1–1 × 106
cells (10.5 µl) with 2 µl of the antibody/serum to be
delivered.
3 Take up electroporation mixture into a 10 µl Neon Pipette Tip
and electroporate using a Neon Electroporator using the
following settings: 1,400 V, 20 ms, 2 pulses. For non-
electroporated controls, skip this step.
4 Transfer electroporated cells to medium supplemented with
10% serum without antibiotics.
5 Seed 1.5 × 104 electroporated cells into 96-well plates in tripli-
cates for RT–qPCRs or 2.5 × 105 cells into 24-well plates for
plaque assays. After 24 h, transfer plates to containment level
3 laboratory (CL3).
6 Remove supernatants and wash wells with PBS to remove
remaining antibodies that could interfere with the virus entry
process.
7 At CL3, infect cells at moi = 1 in DMEM supplemented with
2% FBS and antibiotics.
8 Assess viral RNA loads or production of viral particles after
24 h incubation to allow for single replication cycle (see
below). Plates should be immediately frozen after incubation.
For plaque assays, cells should be freeze/thawed three times
to ensure virions are released.
9 To compare EDNA with classical extracellular neutralization,
incubate sera directly with virus at a range of pfu for 1 h
before adding to cells for 24 h. Assess neutralization by follow-
ing step 8 above.
Plaque assay for SARS-CoV-2
10-fold serial dilutions of viral supernatants were prepared and
used to infect monolayers of Vero ACE2/TMPRSS2 cells. After
1 h of incubation, wells were overlayed with DMEM containing
2% FBS, antibiotics and 0.05% agarose. Cells were incubated for
3 days, fixed with 4% formaldehyde and stained with 0.1% tolu-
idine blue.
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RT–qPCR assay for SARS-CoV-2
After incubation plates were immediately frozen at 70°C to help
with cell lysis. Next, plates were thawed at 4°C and 1 volume of
lysis buffer (0.25% Triton X-100, 50 mM KCl, 100 mM Tris–HCl pH
7.4, glycerol 40% and RNAsecure (1/100) added to wells and mixed
gently by pipetting up and down few times. After 5 min of lysis, cell
lysates were transferred to PCR plates and virus inactivated at 95°C
for 5 min. RT–qPCR were performed with Luna Universal Probe
One-Step kit following manufacturer recommendations. Primer/
probe for genomic viral RNA were CDC-N2. Primer probe for 18S
control were described previously (Ashraf et al, 2006). SARS-CoV-
2_N_Positive control RNA was used as standard for the viral
genomic N reactions. For 18S standard, DNA was synthesized and
kindly gifted by Jordan Clarks and James Stewart (University of
Liverpool). Final concentrations of 500 nM for each primer and
125 nM for the probe were used. RT–qPCRs were run on ABI StepO-
nePlus PCR System with following program: 55°C for 10 min, 95°C
for 1 min and then 40 cycles of 95°C denaturation for 10 s and 60°C
extension for 30 s. RNA copy numbers were obtained from stan-
dards and then genomic copies of N normalized to 1010 copies of
18S. Finally, all data were normalized to 100% negative control.
Generation of TRIM21 KO cells
L929 TRIM21 KO cells were generated using the Alt-R CRISPR-Cas9
system from Integrated DNA technologies (IDT) with a predesigned
crRNA sequence (GAGCCTATGAGTATCGAATG). Guide RNA in the
form of crRNA-tracrRNA duplex was assembled with recombinant
Cas9 protein and electroporated into L929 cells together with Alt-R
Cas9 Electroporation Enhancer. Two days post-electroporation poly-
clonal cells were expanded and also plated one cell per well in 96-
well plates to select single cell clones screened by Western blotting
for TRIM21 protein.
SARS-CoV-2 virus preparation
Virus stock was generated in Vero ACE2/TMPRSS2 cells by infecting
cells at low moi of 0.05 and incubating for three days. Supernatants
were freeze/thawed three times, aliquoted and stored at 70°C.
Titres were assessed by plaque assay. MHV-A59 virus was a kind
gift from Ian Goodfellow (University of Cambridge).
Western blotting
Cells were washed in PBS, lysed in RIPA buffer (CST-9806) or 1%
Triton X-100 supplemented with a protease inhibitor cocktail, spun
at 14,000 g for 10 min and cleared lysates mixed with NuPAGE LDS
Sample Buffer and heated at 95°C for 5 min. Samples were run on
NuPAGE 4–12% Bis-Tris gels and transferred onto nitrocellulose
membrane. For Western blotting of MHV-A59, MHV-A59 polyclonal
antiserum was used that was raised against disintegrated, purified
MHV-A59 virions (Rottier et al, 1981). The serum detects multiple
viral proteins by immunoblot that likely represent the entire MHV-
A59 proteome. Prominent bands at 180, 90 and 50 kDa likely
correspond to full-length spike (S), cleaved spike and nucleoprotein
(N), respectively (Appendix Fig S1E). Antibody incubations were
rabbit anti-MHV serum (1:5,000), mouse anti-MHV N protein
(1:2,000), rabbit anti-TRIM21 (1:1,000) or mouse TRIM21 (1:1,000),
rabbit anti-Vinculin (1:50,000) and rabbit COX IV antibodies
(1:5,000). HRP-coupled secondary anti-mouse light chain-specific
and anti-rabbit light chain-specific antibodies were detected by
enhanced chemiluminescence. For fluorescent detection, we used
secondary antibodies from LICOR and LICOR Odyssey detection
device.
Serum and cell samples
Staff from RPH were recruited through staff email over the course of
2 months: 20 April 2020-10 June 2020, as part of a prospective
study to establish seroprevalence and immune correlates of protec-
tive immunity to SARS-CoV-2 (Ethics Approval: HRA IRAS: 96194
REC: 12/WA/0148). Staff from CUH and QEH were recruited
through the COVID-19 Serology in Oncology Staff (CSOS) study
(Favara et al, 2021a; Favara et al, 2021b) with samples collected in
June, July and December 2020 (Ethics approval: HRA IRAS:
284231). Samples were screened for SARS-CoV-2 N and S binding
antibodies by Luminex assay as previously described (Kemp et al,
2021) and selected for further investigation based on selective bind-
ing profiles.
Serum inactivation
Human serum samples from RPH were inactivated by methylene
blue photochemical treatment. For that, methylene blue was added
to sera at final concentration of 4 lM and illuminated for 15 min
with PMA-Lite LED Photolysis blue light device. Serum samples
from CUH and QEH were heat inactivated at 56°C for 30 min.
Detection and quantification of anti-SARS-CoV-2 antibodies
Inactivated human serum was run on Jess capillary protein detec-
tion system. Serum samples were diluted 20× for the first test.
Higher or lower dilutions were used for consequent runs depending
on antibody signal. To detect S-, S1-, S2-, N- and RBS-specific anti-
bodies, we used SARS-CoV-2 serology assay and separation module
12–240 kDa. Samples were run following manufacturers protocol.
Shortly, protein standard is run in each capillary and in the presence
of specific human antibodies these serve as primary antibodies that
are then detected with anti-human HRP secondary antibody. Bio-
Techne software Compass was used to quantify antibody titres in
the samples.
PBMC isolation and ELISpot
PBMCs were isolated from whole blood collected into Lymphoprep.
ELISpot plates containing PVDF membranes were activated with
15 µl of 35% ethanol for 30 s and washed with distilled water.
Plates were then coated overnight at 4°C with 100 µl of monoclonal
antibodies against IFN-c 5 µg/ml of clone 1-D1K. ELISpot plates
were washed and then blocked with 200 µl R-10 media for at least
3 h. R-10 media: RPMI 1640 supplemented with 10% (v/v), FBS,
2 mM L-glutamine, 100 units penicillin, 0.1 mg/ml streptomycin,
10 mM HEPES buffer and 1 mM sodium pyruvate. At the end of
incubation media was discarded and triplicates of 200,000 periph-
eral blood mononuclear cells (PBMCs) were grown in the presence
or absence of N peptide pool at 1.5 lg/ml final concentration in
100 µl of R-10 media. The peptide mix covers the whole sequence
of the nucleocapsid phosphoprotein. After 16 h of incubation at
37°C, the ELISpot plate was washed followed by incubation with
50 µl biotinylated mouse anti-human IFNc monoclonal antibody
7-B6-1 diluted to 0.5 µg/ml in 0.5% BSA/PBS for 3 h. Captured
IFNc was detected with 50 µl of anti-biotin monoclonal antibody,
diluted 1:750 ml in 0.5% BSA/PBS. After 2 h, plate was washed,
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50 µl of nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate
was added; purple spots appeared within 10 min. Spot numbers
were analysed by an ELISpot reader. Frequencies of Cov-2 Spike-
specific IFNc producing cells were calculated by subtracting the
number of detected spots in the unstimulated sample from the
number of spots detected in the presence of PepTivator SARS-CoV-2
protein N peptide pool (average of triplicates) and were given as
IFNc spot forming cells (SFC)/1 × 106 PBMC.
Flow cytometry
Electroporated fluorescent antibody (IgG-A488) was detected using
an Eclipse EC800 flow cytometer after fixing cells with 4%
formaldehyde at 1 h post-electroporation. Flow cytometry data were
analysed using Eclipse software to obtain mean fluorescence inten-
sity for the entire cell population as well as % cells IgG-A488 posi-
tive by gating against cells electroporated with just PBS.
Microscopy
Cells electroporated with IgG-A488 were washed in fresh media to
remove undelivered antibody and plated on 8-well chambered
coverslips. Cellular IgG-A488 was detected using a Lumascope
LS720 widefield microscope equipped with a 40 × 0.95 NA air
objective, housed within a 37°C, 5% CO2 humidified incubator.
Statistical analysis
Unless otherwise indicated, statistical analyses were performed
using GraphPad Prism 9 software (GraphPad) employing one-way
and two-way ANOVA and least squares fits. Error bars depict the
mean  SEM unless indicated otherwise.
Data availability
This study includes no data deposited in external repositories.
Expanded View for this article is available online.
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